The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2025

Filed:

Jul. 02, 2024
Applicant:

Cerner Innovation, Inc., Kansas City, MO (US);

Inventor:

Douglas S. Mcnair, Leawood, KS (US);

Assignee:

Cerner Innovation, Inc., Kansas City, MO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16H 50/20 (2018.01); G06Q 10/1093 (2023.01); G16H 10/60 (2018.01); G16H 20/30 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01);
U.S. Cl.
CPC ...
G16H 50/20 (2018.01); G06Q 10/1095 (2013.01); G16H 20/30 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 10/60 (2018.01);
Abstract

Systems, methods and computer-readable media are provided for identifying patients having an elevated near-term risk of chronic kidney disease (CKD) progression, including predicting an individual's risk of progression to Stage 3 CKD within a future time interval, which may be up to 36 months. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In an embodiment, measurements of physiological variables are obtained, including serial measurements for uric acid levels from a longitudinal time series of serum or plasma samples spanning the previous two to five years. An annualized uric acid velocity of the patient is determined and used to generate a multivariable mathematical model for determining a likelihood of risk for developing Stage 3 CKD within 36 months.


Find Patent Forward Citations

Loading…